ATE489948T1 - Behandlung von autoimmunkrankheiten - Google Patents

Behandlung von autoimmunkrankheiten

Info

Publication number
ATE489948T1
ATE489948T1 AT06793341T AT06793341T ATE489948T1 AT E489948 T1 ATE489948 T1 AT E489948T1 AT 06793341 T AT06793341 T AT 06793341T AT 06793341 T AT06793341 T AT 06793341T AT E489948 T1 ATE489948 T1 AT E489948T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
AT06793341T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE489948T1 publication Critical patent/ATE489948T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06793341T 2005-09-09 2006-09-07 Behandlung von autoimmunkrankheiten ATE489948T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE489948T1 true ATE489948T1 (de) 2010-12-15

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06793341T ATE489948T1 (de) 2005-09-09 2006-09-07 Behandlung von autoimmunkrankheiten

Country Status (28)

Country Link
US (1) US20080200438A1 (de)
EP (2) EP2295049B1 (de)
JP (4) JP5244598B2 (de)
KR (3) KR20140117704A (de)
CN (1) CN101257899B (de)
AT (1) ATE489948T1 (de)
AU (2) AU2006289100B2 (de)
BR (1) BRPI0615906A2 (de)
CA (2) CA2820510A1 (de)
CY (1) CY1111285T1 (de)
DE (1) DE602006018629D1 (de)
DK (2) DK2295049T3 (de)
ES (2) ES2357426T3 (de)
IL (2) IL189665A (de)
JO (1) JO2655B1 (de)
MA (1) MA29787B1 (de)
MX (1) MX2008003170A (de)
NO (1) NO20081727L (de)
NZ (2) NZ566137A (de)
PL (2) PL1926483T3 (de)
PT (2) PT2295049E (de)
RU (2) RU2424795C2 (de)
SG (1) SG165364A1 (de)
SI (2) SI1926483T1 (de)
TN (1) TNSN08103A1 (de)
TW (2) TWI372620B (de)
WO (1) WO2007028821A2 (de)
ZA (1) ZA200801694B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP2511262B1 (de) 2004-10-12 2017-02-01 Kyorin Pharmaceutical Co., Ltd. Verfahren zur herstellung von 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorphenyl]ethyl]-1,3-propandiol-hydrochlorid
PT1932522E (pt) * 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MY146775A (en) * 2006-08-08 2012-09-28 Kyorin Seiyaku Kk Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
SG174028A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008099781A1 (ja) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
KR20110049870A (ko) * 2008-08-18 2011-05-12 노파르티스 아게 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체
CN102869353A (zh) * 2010-05-06 2013-01-09 诺瓦提斯公司 自身免疫疾病的治疗
CA2794607A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
WO2004026817A1 (ja) 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
NZ538842A (en) * 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
EP2172472B1 (de) * 2003-02-18 2012-12-26 Kyorin Pharmaceutical Co., Ltd. Aminophosphonsäurederivat, Salz davon und S1P-Rezeptormodulator
BRPI0409250B8 (pt) * 2003-04-08 2022-01-18 Mitsubishi Pharma Corp Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
PL1660449T3 (pl) * 2003-08-28 2010-05-31 Novartis Ag Pochodne aminopropanolu
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2009507810A (ja) 2009-02-26
KR20080046231A (ko) 2008-05-26
IL233328A0 (en) 2014-08-31
CN101257899B (zh) 2012-10-03
JP5244598B2 (ja) 2013-07-24
AU2010224355B2 (en) 2012-03-29
PT2295049E (pt) 2015-03-02
NO20081727L (no) 2008-06-06
KR20140117704A (ko) 2014-10-07
AU2006289100B2 (en) 2010-07-22
SI2295049T1 (sl) 2015-03-31
SI1926483T1 (sl) 2011-04-29
BRPI0615906A2 (pt) 2011-05-31
PL1926483T3 (pl) 2011-05-31
TWI376223B (en) 2012-11-11
TW201034659A (en) 2010-10-01
CA2820510A1 (en) 2007-03-15
IL189665A (en) 2014-07-31
JO2655B1 (en) 2012-06-17
CA2620554A1 (en) 2007-03-15
PL2295049T3 (pl) 2015-04-30
CA2620554C (en) 2013-12-17
RU2493840C2 (ru) 2013-09-27
CN101257899A (zh) 2008-09-03
JP6077265B2 (ja) 2017-02-08
TWI372620B (en) 2012-09-21
KR101476451B1 (ko) 2014-12-24
TW200803829A (en) 2008-01-16
DK1926483T3 (da) 2011-03-14
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
DK2295049T3 (en) 2015-02-23
RU2011111117A (ru) 2012-09-27
NZ588372A (en) 2012-03-30
IL189665A0 (en) 2008-06-05
ES2357426T3 (es) 2011-04-26
MA29787B1 (fr) 2008-09-01
WO2007028821A2 (en) 2007-03-15
NZ566137A (en) 2011-05-27
JP2015025002A (ja) 2015-02-05
MX2008003170A (es) 2008-03-18
RU2424795C2 (ru) 2011-07-27
KR20140019033A (ko) 2014-02-13
EP2295049A1 (de) 2011-03-16
PT1926483E (pt) 2011-03-03
EP2295049B1 (de) 2014-11-26
AU2010224355A1 (en) 2010-10-14
CY1111285T1 (el) 2015-08-05
JP2013010802A (ja) 2013-01-17
ZA200801694B (en) 2009-09-30
SG165364A1 (en) 2010-10-28
EP1926483A2 (de) 2008-06-04
TNSN08103A1 (en) 2009-07-14
EP1926483B1 (de) 2010-12-01
AU2006289100A1 (en) 2007-03-15
DE602006018629D1 (de) 2011-01-13
RU2008113187A (ru) 2009-10-20
JP2017019854A (ja) 2017-01-26
ES2529724T3 (es) 2015-02-25
WO2007028821A3 (en) 2007-05-03
HK1149906A1 (en) 2011-10-21

Similar Documents

Publication Publication Date Title
IL233328A0 (en) Treatment of autoimmune diseases
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
TW200509892A (en) Novel aminobenzophenone compounds
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
EA200802054A1 (ru) Ингибиторы фермента
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1926483

Country of ref document: EP